Atopic Dermatitis Clinical Trials in Indianapolis, Indiana

6 studies are recruiting for atopic dermatitis in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating TRIV-573 in Atopic Dermatitis

   The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duratio…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Triveni Bio Site #2, Indianapolis, Indiana

   Locations

   17 in total

   Run by

   Triveni Bio

   See if you can join NCT07782333 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

   The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking partic…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana

   Locations

   32 in total

   Run by

   Pfizer

   See if you can join NCT07783425 on ClinicalTrials.gov

3. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

   This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana

   Locations

   39 in total

   Run by

   Pfizer

   See if you can join NCT06807281 on ClinicalTrials.gov

4. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

5. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

   This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Enveda Investigative Site, Indianapolis, Indiana

   Locations

   9 in total

   Run by

   Enveda Therapeutics

   See if you can join NCT07643766 on ClinicalTrials.gov

6. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site 8142, Indianapolis, Indiana

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov